Currently, galectin is considered a potential target for the early treatment of many liver diseases as it directly activates NLRP3 inflammatory vesicles, which play a key role in liver fibrosis (Mackinnon et al., 2023). This evidence concerns the gene NLRP3 and liver disorder.